Moderna stock price has already corrected more than 30% from 196 level reached a month ago. Shares of companies developing COVID-19 vaccines are falling as the rate of disease and, consequently, demand for the vaccine has declined compared to the peak of the pandemic. In addition, Moderna is once again involved in lawsuits, this time against BioNTech and Pfizer for the rights to the messenger RNA technology.
From a technical perspective, however, Moderna stock price and the DeMarker indicator have formed a bullish divergence, which could allow Moderna to break its downtrend and briefly reverse towards the 147.5 level.
This content is for informational purposes only and is not intended to be investing advice.
